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Abstract
Little is known about the co-prevalence of obsessive compulsive symptoms (OCS) and motor symptoms in patients with 
psychotic disorders. Cross-sectional associations between OCS and motor symptoms were assessed at baseline and at 
3 years follow-up in patients (n = 726) with psychotic disorders and in their unaffected siblings (n = 761) from the Dutch 
Genetic Risk and Outcome of Psychosis (GROUP) study. Furthermore, longitudinal associations between changes in OCS 
and motor symptoms were evaluated. At baseline, OCS was not associated with any motor symptom (akathisia, dyskinesia, 
parkinsonism or dystonia) in patients. At follow-up, patients with OCS reported significantly more akathisia. Dividing the 
patients into four groups—no OCS, OCS remission with OCS only at baseline, OCS de novo with OCS only at follow-up 
and a persistent OCS group—revealed that the OCS de novo group already reported more akathisia at baseline compared to 
the no-OCS group. At follow-up, both the OCS de novo and the persistent OCS group reported more akathisia. These results 
remained significant after correcting for relevant confounders clozapine, GAF score, PANSS-negative score and IQ. Motor 
symptoms at baseline were significantly associated with OCS at follow-up, but not the other way around. In siblings, OCS 
at baseline was associated with akathisia, but this association was lost at follow-up. Results suggest that motor symptoms 
might precede co-occurring OCS in patients with psychotic disorders. However, no inference can be made about causality, 
and further prospective research is needed to investigate this assumption.
Keywords Psychotic disorders · Schizophrenia · Obsessive compulsive disorder · Obsessive compulsive symptoms · Motor 
symptoms · Akathisia
Introduction
Since the introduction of the DSM-III-R in the 1990s which 
allowed for comorbid diagnosis with schizophrenia, there 
has been an increasing research interest in the combination 
of psychosis and obsessive compulsive symptoms (OCS). 
Comorbid obsessive compulsive disorder (OCD) in schizo-
phrenia is present in about 13.5% of cases [1, 43], roughly 
six times more than in the general population [20]. Con-
versely, in OCD the increased risk of developing schizophre-
nia is 6.9 [26]. Curiosity regarding the nature and possible 
implications of the co-existence of the two disorders has led 
researchers to explore potentially related characteristics. A 
strong and persistent association between OCS and specific 
other characteristics in patients and their siblings would sup-
port the hypothesis that the combination of schizophrenia 
and OCS forms a distinct subtype [7]. Like neurocognition 
[37] or severity of psychotic symptoms [10], one of the char-
acteristics of interest in research concerning OCS comorbid-
ity in psychosis concerns motor symptoms.
The first description of motor symptoms, specifically par-
kinsonism, akathisia, dyskinesia, catatonia and dystonia in 
schizophrenia dates back to over a century ago. Parkinson-
ism is a condition of tremor, motor rigidity and poverty of 
motion. Akathisia is a feeling of restlessness and an urgent 
need to move. Dyskinesia is a condition of involuntary 
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repetitive dyskinetic movements. Catatonia is a state of 
immobility, and dystonia consists of sustained or repetitive 
muscle contractions. First-generation anti-psychotic drugs, 
specifically, are associated with motor side-effects. However, 
in the mid-1980s a group of 47 anti-psychotic naïve chronic 
patients was studied. Their prevalence of tardive dyskinesia 
was 51%, only slightly less than matched patients on anti-
psychotics [47]. Ever since, motor symptoms are regarded as 
being commonly present during the course of schizophrenia, 
and only partially linked to anti-psychotic use.
OCD is known to be associated with primary movement 
disorders, manifesting tics and chorea. Tourette’s syndrome 
is the most prominent example [23]; others are Sydenham’s 
chorea [42], Huntington’s disease [2] and potentially Par-
kinson’s disease [24]. Unlike schizophrenia though, “plain” 
OCD is not specifically associated with motor symptoms 
apart from the above-mentioned motor syndromes and 
tics. In short, both schizophrenia and OCD are associated 
with motor symptoms, but the type of motor symptoms dif-
fers. OCD is associated with tics/Tourette’s syndrome and 
Huntington’s disease, but in patients with schizophrenia 
other motor symptoms are more characteristic, such as ste-
reotypies, catatonia and extrapyramidal signs. As in OCD, 
the inhibitory system is involved in tics. In schizophrenia, 
the motor involvement and related lesions are more exten-
sive. Dysregulation of dopaminergic neurotransmission in 
the basal ganglia is thought to be involved in schizophrenia, 
OCD and motor symptoms. Abnormalities in the orbito-
frontal cortex [36] and the cortico-striato-thalamic-cortical 
circuitry are relatively OCD specific, while in schizophre-
nia the neurobiological system involved concerns the frontal 
cortex, basal ganglia, thalamus and cerebellum, the dorsolat-
eral prefrontal cortex, (pre-)motor cortex and the connecting 
white matter tracts [12, 45]. A link between schizophrenia 
and comorbid OCS and motor symptoms is logical because 
both disorders are associated with motor symptoms.
To the best of our knowledge, eight studies have addressed 
motor symptoms in schizophrenia patients with OCS [22, 27, 
28, 30, 33, 34, 39, 44] (Table 1). The results of these studies 
appear to be inconclusive; with regard to parkinsonism and 
Table 1  Previous findings concerning the association between OCS and motor symptoms in patients with psychotic disorders
AIMS Abnormal Involuntary Movement Scale, BAS Barnes Akathisia Scale, HAS Hillside Akathisia Scale, SARS Simpson-Angus Rating Scale, 
CRS Bush-Francis Catatonia Rating Scale, ESRS Extrapyramidal Symptom Rating Scale, NA not addressed
+ Significant association
− Non-significant association
First author; publication year; no. 
of patients
Dyskinesia Akathisia Dystonia Parkinsonism Catatonia
Mean AIMS (SD) Mean BAS (SD) Mean SARS (SD)
Krüger 2000, n = 76 + (AIMS) + (HAS) NA + (SARS) + (CRS)
 − OCS 0.5 (0.8) 4.4 (4.0)
 + OCS 1.6 (1.2) 7.5 (8.8)
Mukhopadaya 2009, n = 59 + (AIMS) NA NA + (SARS) NA
 − OCS 1.3 (2.9) 2.6 (2.6)
 + OCS 4.4 (4.4) 5.1 (3.3)
Ohta 2003, n = 61 + (AIMS) − (BAS) NA + (SARS) NA
 − OCS 1.7 (2.8) 0.3 (0.9) 2.5 (3.0)
 + OCS 6.2 (8.1) 0.2 (0.6) 4.3 (4.8)
Patel 2010, n = 22 + (AIMS) p = 0.06 NA NA − (SARS) NA
 − OCS 5.3 (2.8) 2.1 (2.2)
 + OCS 8.5 (6.4) 2.0 (2.0)
Poyurovsky 2001, n = 68 − (AIMS) − (BAS) NA NA NA
 − OCS 2.7 (2.9) 0.3 (0.7)
 + OCS 3.3 (3.7) 0.4 (1.1)
Poyurovsky 2007, n = 110 − (AIMS) NA NA − (SARS) NA
 − OCS 0.1 (0.7) 10.0 (1.2)
 + OCS 0.4 (1.3) 9.9 (1.2)
Sevincok 2006 n = 57 − (AIMS) − (BAS) NA − (SARS) NA
 − OCS 0.0 0.0 0.0
 + OCS 0.0 0.0 0.0
Tibbo 2000, n = 52 − (ESRS) NA −  (ESRS) + (ESRS), p = 0.08 NA
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dyskinesia, about half the studies report significant higher 
prevalence’s in patients with comorbid OCS. Concerning dys-
tonia [44] and catatonia [22], only one study reported results.
The aim of the current study is to evaluate if and to what 
extent, the presence of OCS in patients and in their unaffected 
siblings is associated with the presence of more various motor 
symptoms (dystonia, akathisia, dyskinesia and parkinson-
ism). Siblings of patients with schizophrenia have a higher 
than average liability for psychosis. With regard to most signs 
and symptoms associated with schizophrenia, siblings have 
an in-between-position—less severe than patients, but more 
severe than controls—while, on the other hand, the siblings 
are free of confounding influences of the psychotic illness and 
anti-psychotic medication. The fact that motor symptoms are 
strongly associated with anti-psychotic medication—as well 
as OCS to a somewhat lesser extent—makes it interesting to 
evaluate whether findings in patients are also found in their 
healthy siblings. First, we will evaluate the cross-sectional 
relationship at baseline between OCS and motor symptoms in 
patients and their siblings. Second, we will examine whether 
the course of OCS is associated with a similar course of motor 
symptoms in patients and their siblings. We will divide the 
patients into four groups: a group with no OCS, with persistent 
OCS and two “changing” groups—with OCS at just one of the 
two assessments. Subsequently, we will determine whether 
motor symptoms change along with OCS. Third, we will seek 
to establish whether OCS at baseline predicts motor symptoms 
3 years later and vice versa, in both patients and siblings.
To the best of our knowledge, no study has evaluated the 
course of motor symptoms and the relationship with OCS 
over time. Nor has the association between OCS and motor 
symptoms been assessed in healthy relatives of patients with 
schizophrenia. Identifying associations between motor symp-
toms and OCS in patients with schizophrenia, and providing 
longitudinal insight into the course of OCS and motor symp-
toms may have important treatment implications, such as 
the choice of antipsychotic medication. Furthermore, it adds 
information to the discussion concerning “the schizo-obsessive 
subtype”. Moreover, if comparable associations between OCS 
and motor symptoms are found in siblings and patients, this 
would support the hypothesis that an OCS–motor symptom 
association is at least partly independent of the confound-
ing effect of medication. Since overlapping brain circuits are 
associated with OCS, motor symptoms and schizophrenia, the 




The study sample was part of the multicenter study 
‘Genetic Risk and Outcome in Psychosis’ (GROUP), 
in which about 1000 patients and 1000 siblings were 
included. Baseline and 3-year follow-up assessments of 
patients and siblings with complete data on relevant out-
come measures were included in the current study. The 
recruitment procedure and population characteristics have 
been described in detail elsewhere [21]. In short, inclu-
sion criteria for patients and siblings were (1) age range 
of 16–50 years and (2) good command of the Dutch lan-
guage. Patients had to meet DSM-IV-TR criteria for a non-
affective psychotic disorder [4] which was assessed with 
the Comprehensive Assessment of Symptoms and History 
(CASH [3]) in three out of the four testing sites or the 
Schedules for Clinical Assessment for Neuropsychiatry 
version 2.1 (SCAN [48]) in one out of the four sites. An 
additional inclusion criterion for the sibling group was the 
absence of a lifetime psychotic disorder. All participants 
provided written informed consent prior to their inclusion 
in the study, which was approved by the accredited Medi-
cal Ethics Review Committee (METC).
Clinical measures
Sociodemographic data on age, gender, education level, 
age of onset, duration of illness, and medical treatment 
were collected. Diagnosis according to DSM-IV was 
assessed. Current diagnosis of cannabis abuse and depend-
ence was assessed using the Composite International 
Diagnostic Interview (CIDI [29]). Severity of positive 
and negative symptoms and general psychopathology in 
patients were evaluated with the Positive and Negative 
Syndrome Scale (PANSS [19]) according to the three-fac-
tor model. The Community Assessment of Psychic Expe-
riences (CAPE [41]), a 42-item self-report questionnaire, 
was used to establish the frequency and associated distress 
with mild psychotic experiences in siblings.
A neuropsychological test-battery with seven cognitive 
tasks based on subtests of the Wechsler Adult Intelligence 
Scale-Third Edition (WAIS-III [46]) was administered, 
resulting in an IQ-score.
Severity of OCS was measured with the Yale-Brown 
Obsessive Compulsive Scale (YBOCS [16]), which has been 
validated for the assessment of OCS in schizophrenia [8, 11]. 
Based on interpretation guidelines, we defined the presence 
of clinically relevant OCS as a YBOCS total score of at least 
8, representing mild symptom severity [16].
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The motor section of the Unified Parkinson Disease 
Rating Scale (UPDRS) was used to assess parkinsonism 
[25]. A total score of at least 14 on the UPDRS and at least 
one item scored as mild symptoms was required to qualify 
as mild parkinsonism. The Abnormal Involuntary Move-
ment Scale (AIMS [17]) was used to assess dyskinesia One 
item scoring at least mild ≥ 1 on the AIMS was required to 
qualify as mild dyskinesia. Akathisia was assessed using 
the Barnes Akathisia Rating Scale (BARS) [6]. To qualify 
as mild akathisia, the BARS global score, a composite 
overall severity score requiring both subjective and objec-
tive symptoms to be present, needed to be at least mild 
(≥ 2). One item was added to the BARS to measure acute 
dystonia with a severity score from 0 to 4. For the BARS 
dystonia scale again a mild symptom score, ≥ 1, was 
required to qualify as dystonia. A composite motor score 
was generated, defined as having at least one motor symp-
tom scored as “mild” on any of the mentioned instruments 
assessing motor symptoms. To obtain enough power, we 
lowered the threshold for siblings on the Y-BOCS and the 
motor symptom scales to any score.
Before the start of the study all interviewers participated 
in extensive training workshops to practice the assessments 
of all measures used in the GROUP project (for detail see 
[21]).
Statistical analysis
Statistical analyses were performed using the Statistical pack-
age for Social Sciences (SPSS version 23.0, Chicago, IL, US). 
Pearson Chi-Square tests, T test and logistic regression were 
used when appropriate, to determine demographic, illness 
characteristics and prevalences. Estimates were adjusted for 
potential confounders (gender, age, ethnicity, marital status, 
education level, IQ, and in patients—GAF-scores, clozapine 
and first-generation anti-psychotic use, anti-depressant use, 
duration of illness and PANSS scores; and in siblings—CAPE 
scores). Because of potential overlap, the PANSS-general scale 
score was not entered as a confounder. Confounding varia-
bles were entered successively in the logistic regression with 
motor symptoms as the independent variable and the OCS 
status as the dependent variable. The potential confound-
ers were included in the analyses if they had a meaningful 
impact on the effect estimate (defined as more than 5%) or 
if the model fit significantly improved (− 2 log likelihood 
method), and were included in the final models. Confounders 
were selected for patients and siblings and the two assessment 
periods, separately. In patients and siblings, sociodemographic 
and clinical characteristics were compared between subjects 
with OCS and without OCS using Pearson Chi-square tests 
and T tests. The cross-sectional association between OCS and 
motor symptoms was assessed using logistic regression, with 
and without correction for confounders. For the longitudinal 
pairwise comparison between OCS change-groups and motor 
symptoms in patients, we used the Pearson Chi-square test and 
logistic regression to assess prevalences and odds ratios, again 
with and without correction for confounders. The cross-assess-
ment cross-symptom associations in patients and siblings were 
evaluated using logistic regression.
Results
Sociodemographic and clinical characteristics 
in patients
Data were present on both OCS and motor symptoms at both 
baseline assessment and 3-year follow-up for 726 patients. 
At least one motor symptom was scored as mild during at 
least one assessment in 344 patients (47.4%), while 182 
patients (25.1%) had OCS in at least one assessment. OCS 
at baseline were present in 106 patients and OCS at follow-
up were present in 117 patients. Of these 41 had OCS at both 
assessments. At baseline 252 patients had motor symptoms 
and 210 at follow-up, of whom 102 had persistent motor 
symptoms.
Table 2 presents the socio-demographic and clinical char-
acteristics of patients with and without OCS at baseline. 
Patients with OCS more often used anti-depressants, more 
often used clozapine, had lower GAF-scores and higher 
scores on all three PANSS scales (Table 2).
Sociodemographic and clinical characteristics 
in unaffected siblings
Data were present on both OCS and motor symptoms at both 
the baseline assessment and the 3-year follow-up for 761 
siblings. Of the unaffected siblings, 98 (14.2%) had OCS 
during at least one assessment. Any score on a motor symp-
tom scale was present in 350 (46.0%) siblings for at least 
one assessment. At baseline 55 siblings had OCS and 67 had 
OCS at follow-up. Of these 14 had OCS at both assessments. 
At baseline 232 siblings had motor symptoms and 244 at 
follow-up, of whom 126 had persistent motor symptoms.
Table 3 presents the socio-demographic and clinical char-
acteristics of siblings with and without OCS at baseline. 
Siblings reporting OCS at baseline showed higher CAPE 
scores, but did not differ significantly on other demographic 
or clinical characteristics (Table 3).
Cross‑sectional association between OCS and motor 
symptoms at baseline and 3‑year follow‑up 
in patients
To assess the association between OCS and motor symp-
toms, we used logistic regression analyses calculating odds 
ratios. The following potential confounders were entered in 
261European Archives of Psychiatry and Clinical Neuroscience (2019) 269:257–268 
1 3
the logistic regression: gender, age, ethnicity, marital status, 
education level, IQ, GAF-scores, clozapine and first-gen-
eration anti-psychotic use, anti-depressant use, duration of 
illness and PANSS scores. For the baseline assessment, only 
GAF-score, clozapine use and the PANSS-negative score 
were identified as confounders, using the composite motor 
scale as independent variable and OCS status as outcome.
At baseline, the presence of OCS showed no significant 
association with any of the motor scales assessed. This result 
remained unchanged after adjusting for the identified con-
founders (Table 4).
For the follow-up assessment, GAF-score, IQ and 
PANSS-negative score were identified as confounders. The 
PANSS-positive was entered as a potential confounder for 
both assessments, but did not independently contribute to 
the model.
At follow-up, OCS was positively associated with the 
composite motor scale and akathisia; presence of OCS 
raised the odds for suffering from motor symptoms by 
1.8 (CI 1.2–2.8, p = 0.004), and from akathisia by 2.4, 
(CI 1.3–4.5, p = 0.005), respectively. The other motor 
Table 2  Differences in patient characteristics at baseline and follow-up associated with OCS status
*p ≤ 0.05
**p ≤ 0.01
Patient n = 726 Baseline Follow-up
OCS −, n = 620 
(85.4%)
OCS +, 
n = 106 
(14.6%)
OCS −, n = 609 
(83.9%)
OCS +, 
n = 117 
(16.1%)
Gender (male) 468 (75.5%) 84 (79.2%) χ2 = 0.7 (1), p = 0.402 461 (75.7%) 91 (77.8%) χ2 = 0.23 (1), p = 0.629
Age (mean, sd) 27.5 (7.4) 26.4 (6.7) (t = 1.5, p = 0.145) 30.8 (7.6) 30.0 (5.9) (t = 1.0, p = 0.321)
Duration of illness 
(mean, sd)
4.3 (4.2) 5.0 (3.5) (t = − 1.5, p = 0.127)
Education level χ2 = 3.0 (3), p = 0.386
 Primary school or 
missing
68 (11.0%) 15 (14.1%)
 Secondary basic 376 (60.6%) 69 (65.1%)
 Secondary 
advanced/college
176 (28.4%) 22 (20.8%)
Ethnicity (Caucasian) 511 (82.4%) 84 (79.2%) χ2 = 0.6 (1), p = 0.532
Marital status (with 
partner)
63 (10.2%) 5 (4.7%) χ2 = 3.2 (2), p = 0.206
Clozapine use 93 (16.2%) 27 (27.8%) χ2 = 7.6 (1), 
p = 0.006**




153 (26.6%) 24 (24.7%) χ2 = 0.2 (1), p = 0.686 67 (13%) 16 (14.7%) χ2 = 0.2(1), p = 0.636
Antidepressant use 79 (13.9%) 22 (22.2%) χ2 = 4.5 (1), p = 0.03* No information
Cannabis use 118 (19.0%) 18 (17.0%) χ2 = 0.3 (1), p = 0.617 51 (8.4%) 9 (7.7%) χ2 = 0.06(1), p = 0.806
IQ (mean, sd) 96.5 (16.2) 95.9 (15.3) (t = 0.4, p = 0.709) 99.3 (16.8) 96.9 (16.6) (t = 1.3, p = 0.212)
GAF (mean, sd) 57.8 (15.7) 51.8 (16.9) (t = 3.4, p = 0.001)** 62.5 (15.7) 52.1 (14.7) (t = 6.3, p < 0.0005)**
PANSS positive scale 
(mean, sd)
11.8 (5.0) 14.4 (5.5) (t = −4.9, 
p < 0.0005)**




13.2 (5.7) 14.5 (5.6) (t = − 2.1, p < 0.035)* 11.5 (5.0) 12.7 (4.8) (t = −2.5, p < 0.013)*
PANSS general scale 
(mean, sd)
26.2 (7.7) 31.2 (8.2) (t = −6.0, 
p < 0.001)**




203 (32.7%) 39 (36.8%) χ2 = 0.67 (1), 
p = 0.414
163 (26.7%) 47 (40.2%) χ2 = 8.60 (1), 
p = 0.003**
Akathasia 49 (7.9%) 13 (21.0%) χ2 = 2.2 (1), p = 0.14 37 (6.1%) 16 (13.7%) χ2 = 8.42 (1), 
p = 0.004**
Dystonia 21 (3.4%) 5 (4.7%) χ2 = 0.5 (1), p = 0.691 20 (3.3%) 6 (5.1%) χ2 = 0.97 (1), p = 0.326
Dyskinesia 125 (20.2%) 23 (21.7%) χ2 = 0.1(1), p = 0.717 92 (15.1%) 25 (21.4%) χ2 = 2.85 (1), p = 0.09
Parkinsonism 67 (10.8%) 11 (10.4%) χ2 = 0.0(1), p = 0.895 70 (11.5%) 21 (17.9%) χ2 = 3.73 (1), p = 0.053
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symptoms were not significantly associated with the pres-
ence of OCS. After adjusting for the identified confounders 
only the association between OCS and akathisia remained 
significant (OR 2.2, CI 1.1–4.4, p = 0.033) (Table 4).
Cross‑sectional association between OCS and motor 
symptoms at baseline and 3‑year follow‑up 
in unaffected siblings
Note that OCS and motor symptom cut-offs for siblings are 
Table 3  Differences in sibling characteristics at baseline associated with OCS status
Sibling characteristics at baseline (n = 761) OCS −, n = 706 (92.8%) OCS +, n = 55 (7.2%)
Gender (male) 317 (44.9%) 17 (30.9%) χ2 = 4.1 (1), p = 0.044*
Age (mean, sd) 27.6 (8.2) 28.1 (5.9) t = − 0.4, p = 0.671
Education level χ2 = 6.3 (3), p = 0.100
 Primary school or missing 48 (6.8%) 3 (5.5%)
 Secondary (VMBO HAVO MBO) 365 (51.7%) 20 (36.4%)
 Secondary advanced level or college 293 (41.5%) 32 (58.2%)
Ethnicity (Caucasian) 616 (87.3%) 48 (87.3%) χ2 = 0.0 (1), p = 0.996
Marital status (with partner) 277 (39.2%) 23 (41.8%) χ2 = 1.5 (1), p = 0.457
Cannabis use 33 (4.7%) 1 (1.8%) χ2 = 1.0 (1), p = 0.323
IQ (mean, sd) 104.3 (15.7) 103.9 (15.4) t = 0.2, p = 0.864
CAPE positive (mean, sd) 0.19 (0.18) 0.25 (0.25) t = − 2.4, p = 0.015*
CAPE negative (mean, sd) 0.54 (0.37) 0.75 (0.49) t = − 3.8, p = 0.000**
CAPE depressive (mean, sd) 0.62 (0.38) 0.81 (0.50) t = − 3.8, p = 0.001**
Composite scale any motor sympt 214 (30.3%) 18 (32.7%) χ2 = 0.1(1), p = 0.708
Akathisia 22 (3.1%) 6 (10.9%) χ2 = 8.7(1), p = 0.003**
Dystonia 5 (0.7%) 0(0%) χ2 = 0.4(1), p = 0.531
Dyskinesia 60 (8.5%) 5 (9.1%) χ2 = 0.0(1), p = 0.880
Parkinsonism 180 (25.5%) 15 (27.3%) χ2 = 0.1 (1), p = 0.771
Table 4  Results of naïve logistic regression analyses, comparing mild motor symptoms in patients and siblings without OCS with patients with 
OCS at baseline and follow-up
a Included confounders patients T0: GAF score, clozapine use, PANSS-negative
b Included confounders patients T1: GAF score, IQ, PANSS-negative
c Included confounders siblings T0: gender
d Included confounders siblings T1: marital status
*p ≤ 0.05
**p ≤ 0.01
Unadjusted model T0 Fully adjusted model T0 Unadjusted model T1 Fully adjusted model T1
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Patients
 Composite scale 1.2 (0.8–1.8) 0.7 (0.6–1.5)a 1.8 (1.2–2.8)** 1.3 (0.8–2.1)b
 Mild akathisia 1.6 (0.8–3.1) 1.3 (0.6–2.8)a 2.4 (1.3–4.6)** 2.2 (1.1–4.4)b,*
 Mild dystonia 1.4 (0.5–3.8) 1.5 (0.5–4.2)a 1.6 (0.6–4.1) 0.7 (0.2–2.6)b
 Mild parkinsonism 1.0 (0.5–1.9) 0.8 (0.4–1.7)a 1.7 (1.0–2.9) 0.9 (0.4–1.8)b
 Mild dyskinesia 1.1 (0.7–1.8) 0.9 (0.5–1.6)a 1.5 (0.9–2.5) 1.4 (0.8–2.5)b
Siblings
 Composite scale 1.1 (0.6–2.0) 1.2 (0.7–2.2)c 1.0 (0.6–1.8) 1.0 (0.6–1.7)d
 Akathisia 3.8 (1.5–9.8)** 3.8 (1.5–9.9)c,** 1.6 (0.5–5.5) 1.5 (0.4–5.3)d
 Parkinsonism 1.1 (0.6–2.0) 1.2 (0.6–2.2)c 1.2 (0.7–2.1) 1.2 (0.7–2.0)d
 Dyskinesia 1.0 (0.4–1.8) 1.2 (0.4–3.0)c 1.2 (0.5–2.9) 1.2 (0.5–2.8)d
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lower than for patients, which makes direct comparison of 
reported percentages impossible. In siblings at baseline, 
the presence of OCS increased the odds of suffering from 
akathisia by 3.8 (CI 1.5–9.8), which remained unchanged 
after adjusting for the identified confounder gender. The 
other potential confounders, age, ethnicity, marital status, 
education level, IQ and CAPE scores did not have a sig-
nificant effect on the outcome. The other motor symptoms 
showed no significant association with OCS (Table 4).
At the follow-up assessment, marital status was identified 
as a confounder and OCS was no longer associated with any 
motor symptom (Table 4). The sibling sample consisted of 
significantly more females, while the patient sample con-
tained more males. No sibling had a dyskinesia score at any 
assessment.
Longitudinal pairwise comparison between OCS 
change‑groups and motor symptoms in patients
To study the course of OCS and its relationship with the 
course of motor symptoms both OCS and motor symptoms 
were categorized into four groups as was done in our previ-
ous analyses [37, 38]: (1) a no symptom group, (2) a remis-
sion group, showing symptoms at baseline assessment only, 
(3) a de novo group, showing symptoms at follow-up, but 
not at baseline and (4) a persistent group, showing symptoms 
at both assessments. Subsequently, the relationship between 
those groups and motor symptoms was analyzed (Fig. 1). In 
patients, the association between the four OCS-groups and 
the four motor symptom-groups was significant (χ2 = 18.1 
(9), p = 0.034).
Subsequent pair-wise comparisons regarding the four 
OCS-groups revealed that the OCS de novo group signifi-
cantly differed compared to the no-OCS group (χ2 = 10.5 
(3), p = 0.015). The persistent OCS group is very similar to 
the OCS de novo group in motor symptom prevalences, but 
analyses did not reach significance, probably because of the 
group size being almost half the size of the OCS de novo 
group [χ2 = 6.9 (3), p = 0.076]. All other pairwise compari-
sons failed to show a significant association.
To evaluate the effect of the OCS groups on motor symp-
toms at baseline and follow-up, we subsequently performed 
exploratory analyses: a logistical regression focusing on 
those groups and symptoms showing significant results in 
previous analyses. We performed a pair-wise comparison 
between the no-OCS group and the de novo group and the 
no-OCS group and the persistent OCS group, looking at the 
composite motor scale and akathisia at both assessments. 
Table 5 shows the results. Akathisia is associated with both 
the de novo OCS group and the persistent OCS group at 
both assessments; for the persistent group, the association 
loses significance at baseline after correcting for confound-
ers. The composite scale is also associated with the de novo 
and persistent group, but this association loses significance 
after correction for confounders.
Longitudinal association between OCS and motor 
symptoms in siblings
Siblings were grouped according to their OCS or motor 
symptom status (none, remission, de novo or persistent). No 
significant association between OCS and motor symptom 
status were found (Fig. 2). Note that the number of siblings 
scoring on OCS particularly is small, resulting in some very 
small cell counts. Motor symptoms tend to go into remission 
in about 50% of all cases, independent of the OCS status of 
siblings. In siblings, persistent OCS is very rare: only 14 
siblings (1.8%) had OCS at both assessments. Having OCS 
at one assessment is more common, 5.4% at baseline and 
7.0% at follow-up.
Fig. 1  Distribution of motor 
symptom status per OCS status 
group expressed in percent-
age of the OCS group total in 
patients. Information on number 
of patients per group are added
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Cross‑assessment cross‑symptom associations 
in patients and siblings
In patients, the presence of motor symptoms at baseline 
is associated with OCS at follow-up, (OR 1.8, CI 1.2–2.8, 
p = 0.003). Conversely, OCS at baseline is not significantly 
associated with motor symptoms at follow-up (OR 1.5, CI 
0.9–2.2, p = 0.090).
In siblings, motor symptoms at baseline are not sig-
nificantly associated with OCS at follow-up (OR 0.8, 
CI 0.5–1.4, p = 0.501), nor is OCS at baseline associated 
with motor symptoms at follow-up (OR 0.9, CI 0.5–1.6, 
p = 0.860).
Discussion
The main findings of our study are as follows. In patients, 
we found no cross-sectional association between OCS and 
any motor symptoms at baseline, but we did find a cross-sec-
tional association between OCS and akathisia and the com-
posite motor score at follow-up. The association between 
akathisia and OCS remained significant after correcting for 
confounders. In siblings the only significant association was 
again found between the presence of OCS and akathisia, 
however, this association was only present at baseline. When 
divided into four groups, the persistent OCS group and the 
OCS de novo group were associated with more akathisia.
Compared to the results of previous studies (Table 1), it is 
remarkable that we find an association only with akathisia. 
Of the five studies assessing akathisia, only one found a 
significant association. The associations between OCS and 
parkinsonism found in four out of seven previous studies 
and between OCS and dyskinesia found in four out of eight 
studies, on the other hand, were not replicated in the current 
study.
The following factors may explain the differences 
between our results and those of earlier studies.
Comparing AIMS scores for dyskinesia, which were pro-
vided in seven studies we see considerable heterogeneity in 
scores, between zero and 8.5 (Table 1), indicating substantial 
differences between the samples. In our sample at baseline, 
the mean AIMS-score was 0.5 (SD 1.3) in patients without 
OCS and 0.4 (SD 1.0) in patients with co-morbid OCS. This 
is a relatively low score compared to most other studies, 
indicating potential fundamental differences between our 
Table 5  No-OCS group 
compared to the OCS de novo 
group and the persistent OCS 
group regarding their composite 
motor score and akathisia at 
baseline and follow-up
a Corrected for confounders baseline: clozapine, GAF score and PANSS negative
b Corrected for confounders follow-up: PANSS negative, GAF, IQ
*p < 0.05; **p < 0.01
Patients, No-OCS = reference 
group, Unadjusted and adjusted
OCS de novo, OR (95%-CI) Persistent OCS, OR (95%-CI)
Composite scale T0 1.8 (1.1–2.9)* 1.5 (0.9–2.5)a 1.9 (1.0–3.6)* 1.6 (0.8–3.2)a
Mild akathisia T0 2.6 (1.3–5.2)** 2.2 (1.0–4.8)a,* 2.3 (0.9–5.9) 2.0 (0.7–5.6)a
Composite scale T1 1.8 (1.1–3.0)* 1.7 (1.0–3.0)b 2.0 (1.0–3.8)* 1.8 (0.9–3.6)b
Mild akathisia T1 2.7 (1.3–5.8)* 2.6 (1.4–6.1)b,* 3.0 (1.2–7.8)* 2.3 (0.8–6.7)b
Fig. 2  Distribution of motor 
symptom status per OCS status 
group expressed in percentage 
of the OCS group total in sib-
lings. Information on number of 
siblings per group are added
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study sample and other study samples. The GROUP sample 
with a mean age of 27 years and a 4-year duration of illness 
is relatively young compared to samples from earlier stud-
ies, in which the mean age ranged from 30 to 45 years and 
the duration of illness ranged from 9 to 22 years [28, 32, 
34]. Particularly dyskinesia and to a lesser extent parkin-
sonism may develop over a period of years; therefore, the 
illness duration of our sample might be too short to have 
allowed the development of those motor symptoms. Another 
explanation for the differences with former studies may be 
that anti-psychotic prescription protocols have changed in 
the past 15 years. Modern anti-psychotics have become an 
alternative to classical anti-psychotics, in particular when 
motor side-effects are present, and new insights found that 
first-generation anti-psychotics are best prescribed in much 
lower dosage than had been done previously. In the GROUP 
sample, relatively few patients (about 25%) used first-gener-
ation anti-psychotics, and dosages were relatively low. Both 
the prescription of lower dosages and the option of alter-
native medication with fewer motor symptom side effects 
will have reduced motor symptoms over the course of time, 
resulting in lower motor symptom prevalences in the more 
recent studies.
Our finding that OCS is associated with akathisia, which 
has not been found in previous studies, might be explained 
by our large sample size with enough power to find genuine 
differences. In a previous study, the unexpected emergence 
of akathisia was reported in 40% of SSRI-treated OCD 
patients after they were given one challenge with amisul-
pride (400 mg). In OCD patients the serotonergic transporter 
binding site is reduced compared to healthy volunteers [35], 
while a 20% reduction of dopamine receptor availability in 
the left caudate has been reported [13]. The modern anti-
psychotics not only block the dopamine receptors but also 
interact with the different serotonin receptors [15]. Since 
OCD patients have deficiencies in both receptor systems, 
a comparable disturbance to those systems may underlie 
the vulnerability of schizophrenia patients with comorbid 
OCS for motor side-effects and potentially motor symp-
toms in general. Furthermore, in a review on drug-induced 
akathisia by Stahlet al. [40], akathisia is linked to a decrease 
in dopaminergic neurotransmission, which through a com-
pensatory enhancement of adrenergic projections, results in 
a mismatch of activity between the shell and the nucleus of 
the nucleus accumbens. Although OCD is associated with 
the whole cortico-striato-thalamic-cortical circuitry [12, 31], 
Figee et al. found specific differences in the nucleus accum-
bens activity between OCD patients and healthy volunteers 
[14]. Therefore, a malfunctioning of the nucleus accumbens 
could possibly explain the co-occurrence between OCS and 
motor symptoms we find in our study in both patients and 
their siblings.
An alternative explanation might be that overlap between 
OCS and akathisia results in false positive cases. Specifi-
cally, the subjective feeling of restlessness, part of the 
akathisia, is close to the distress seen in patients with the 
urge to control or suppress compulsions in response to intru-
sive thoughts [5]. Little is known about the early course of 
OCD and even less is known concerning the early course of 
OCD in schizophrenia, but a retrospective study reported 
that “anxiety” and “lacking self-trust” were frequent first 
signs of developing OCD [18]. Specifically, the anxiety 
could partially overlap with mild akathisia. This could 
explain why the de novo-group has relatively high akathisia 
scores at baseline, without the OCS being present yet. The 
fact, though, that we find no consistent covariation between 
OCS and motor symptoms renders an overlap in symptoms 
unlikely as full explanation for their association.
Longitudinal analyses showed that the difference in asso-
ciation with OCS and motor symptoms in patients, absent 
at baseline but present at follow-up, were mainly driven by 
significantly higher akathisia and composite motor scores in 
the group that developed OCS de novo and in the persistent 
group (Table 5). The strength of the association at follow-
up measured in odds ratios, between OCS and akathisia 
was similar for the persistent group and the de novo group. 
Unlike the de novo and persistent group, the OCS remission 
group did not differ significantly at any assessment regard-
ing its motor symptoms, compared to the no-OCS group. In 
patients, motor symptoms at baseline were associated with 
OCS at follow-up, but not the other way around.
The longitudinal results partly stand in line with results 
of previous analyses from the GROUP data, comparing OCS 
status groups and the course of PANSS and GAF scores [38] 
as well as cognitive functioning over the 3 year assessment 
period [37]. In all three studies at baseline, the group which 
was going to develop OCS at follow-up—the OCS de novo 
group—already showed more impairment than the no-OCS 
group. In the current study, at baseline, the OCS de novo 
group already had more motor symptoms and these symp-
toms persisted over time and remained more or less stable. 
Similar to the motor symptoms, patients in the OCS de novo 
group reported stable higher psychopathology on the PANSS 
and GAF compared to the no-OCS group. On cognitive 
performance, the OCS de novo group had deteriorated on 
the set-shifting task at follow-up, while the OCS remission 
group remained stable or improved on all tasks [25, 26]. This 
is in line with the cross-trait cross-assessment result, show-
ing that in patients motor symptoms at baseline were asso-
ciated with OCS occurrence at follow-up, but not the other 
way around. Taken together, our results might indicate that 
motor symptoms can appear before the emergence of OCS 
along with higher PANSS scores, poorer overall functioning 
and poorer cognitive functioning in certain tasks.
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In unaffected siblings, we also found an association 
between akathisia and OCS, but not with the other motor 
symptoms. It is remarkable that of the five motor symp-
toms assessed, in both patients and siblings, only akathisia 
showed a positive association with OCS, which may indi-
cate a link between akathisia and OCS in psychotic and 
psychosis-prone individuals, which could be explained by 
malfunction of neurobiological areas causing both OCS and 
akathisia. For instance, disturbances in the functioning of the 
nucleus accumbens may underlie both OCS and akathisia.
In siblings, this association is present at baseline, but dis-
appears at follow-up. At baseline, six out of 28 siblings with 
akathisia have OCS. At follow-up, three out of 23 akathisia 
patients had OCS. This small difference of three siblings 
accounts for the presence or absence of a significant associa-
tion, which makes it difficult to draw conclusions. Although 
761 siblings were included and assessed twice, the propor-
tion of siblings with OCS or motor symptoms was small. 
In lowering the threshold to any score on both the motor 
symptom scale and the Y-BOCS, we have probably included 
false positive cases.
Several limitations should be considered in interpreting 
the results of our study. First, the fact that there were only 
two assessments over a 3-year period is an important limita-
tion, because many events with substantial influences on the 
course of illness may have taken place unnoticed in between 
assessments.
Second, although we tried to correct for possible con-
founders, it is unlikely that we were able to correct for all 
influencing variables, while it is possible that we corrected 
for partly overlapping variables. Information on antipsy-
chotic dosage and on anti-cholinergic agents is missing, so 
we were unable to correct for these potential confounders. 
Third, we decided not to correct for multiple comparisons, 
because we compared the three groups on four strongly 
related items and the results are very consistent. Notwith-
standing this, there is a chance that our results are false 
positive. Therefore replication of these results is important 
before strong conclusions can be drawn.
Fourth, the mean severity of OCS and motor symptoms 
is relatively low, especially in the sibling sample. Despite 
these limitations, our current study has many methodo-
logical strengths compared to former studies. Few studies 
assessed the association between co-occurring OCS and 
motor symptoms in patients suffering from schizophre-
nia. Results have been inconsistent, numbers of patients 
included were small and in most studies, only one or two 
motor symptoms were assessed, while no correction for 
possible confounders was made. Until now the longitudinal 
course and interaction of OCS and motor symptoms have 
not been studied nor has this been examined in unaffected 
siblings. Our sample is by far the largest ever to have 
evaluated motor symptoms in patients with schizophre-
nia, with and without OCS. Because of its multi-center 
design including patients from different areas and clinical 
settings in contrast to the previous studies, our results are 
more applicable to the general patient population.
In conclusion, our results show that few motor symp-
toms are associated with OCS in schizophrenia, but sug-
gest that the presence of persistent OCS and OCS de novo 
are associated with akathisia during the course of the ill-
ness. Both at baseline and follow-up, patients with per-
sistent OCS and patients developing OCS de novo have 
more combined motor symptoms and akathisia compared 
to patients without OCS. Moreover, motor symptoms may 
predict OCS at follow-up. In unaffected siblings, we found 
an association between akathisia and OCS at baseline as 
well, which is lost at follow-up. However, although the 
sibling sample is relatively large, severity of OCS or motor 
symptoms in siblings is low, therefore, this finding is not 
robust.
Our results have the following implications: Clini-
cians should be alert to the possibility that patients with 
comorbid OCS might have a higher risk of developing 
akathisia, especially since akathisia is difficult to diag-
nose and can be easily misinterpreted as psychosis-related 
agitation [9]. The fact that the co-occurrence of akathisia 
and OCS is also found in siblings implies that akathisia is 
at least partly caused by factors other than antipsychotic 
medication. In this respect, disturbances of function of the 
nucleus accumbens is of interest. In the future more lon-
gitudinal studies with smaller intervals would help, if our 
results are replicated, in identifying a pattern of emergence 
of symptoms, some of which might have a certain “predic-
tive” value. Finally, patients would benefit from treatment 
trials, identifying optimal medication protocols for the 
treatment of comorbid OCS in schizophrenia, monitoring 
side-effects, such as akathisia.
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